To The Moon: Our Interview With ResearchSat
Recently, I had the chance to sit down and chat with ResearchSat’s founder/CEO RaviTeja Duggineni and their head of investor relations, Rahul Kundnani.
The Might of Mesoblast: How Perseverance Paid Off
Last year, Mesoblast Ltd had their therapeutic RYONCIL approved by the FDA. This article touches on the journey to get to this milestone.
The Micro Apocalypse: Antimicrobial Resistance
Antibiotics are arguably one of the most important biotechnological inventions of the last century. Access to effective antibiotic and antimicrobial drugs has saved countless lives, and allowed for advancements in healthcare, increasing the success of other medical interventions such as surgery and chemotherapy.
Here’s why last week’s stock market crash is a warning sign for Australia’s biotech sector
Investments in biotechnology are most impactful when made by those with deep pockets. The aim of the game is to make a return on investment, which can only occur when biotech companies can create a profitable product. Without funding from angel investors/venture capitalists, many biotech companies cannot continue to meaningfully function. Analysis of the recent …
FightMND’s Beanie to Cure Pipeline: Where does the money go?
Who are FightMND? FightMND are a charity co-founded by Neale Daniher, Pat Cunningham and Dr Ian Davis. The charity aims to raise money to fund important clinical research so that treatments or a cure for MND may be discovered. Since 2014, more than $80 million dollars have been raised by the charity. Much of this …
Read more “FightMND’s Beanie to Cure Pipeline: Where does the money go?”
The PLATYPUS Trail: New MS Clinical Trial Arrives at HMRI
Last week Hunter Medical Research Institute (HMRI) announced that a new MS Clinical trial will begin in Newcastle, headed by Professor Jeanette Lechner-Scott.